Amylyx Pharmaceuticals (NASDAQ:AMLX) Stock Rated "Strong-Buy" in New Coverage at HC Wainwright

Key Points

• HC Wainwright initiated coverage with a “Strong Buy” rating and forecast Amylyx’s quarterly losses to narrow from $0.38 per share in Q1 2027 to $0.32 in Q4 2027. Across analysts, the consensus rating is “Buy” with an average price target of $44.14.
• Amylyx reported a quarterly loss of $0.38 per share, matching analyst expectations; analysts project a full-year loss of $1.48 per share.
• Company insiders sold a combined 60,374 shares worth about $1.82 million over the past three months. Separately, institutional investors own 95.84% of the stock.

Stock analysts at HC Wainwright assumed coverage on shares of Amylyx Pharmaceuticals (NASDAQ:AMLX - Get Free Report) in a note issued to investors on Thursday, Zacks reports. The brokerage set a "strong-buy" rating on the stock. HC Wainwright also issued estimates for Amylyx Pharmaceuticals' Q1 2027 earnings at ($0.38) EPS, Q2 2027 earnings at ($0.37) EPS, Q3 2027 earnings at ($0.35) EPS and Q4 2027 earnings at ($0.32) EPS.

AMLX has been the subject of a number of other reports. Mizuho upped their price objective on Amylyx Pharmaceuticals from $30.00 to $42.00 and gave the stock an "outperform" rating in a report on Tuesday, August 18th. Robert W. Baird boosted their price objective on Amylyx Pharmaceuticals from $28.00 to $52.00 and gave the stock an "outperform" rating in a research note on Wednesday, August 19th. Stifel Nicolaus set a $45.00 target price on shares of Amylyx Pharmaceuticals in a research report on Thursday. Citigroup increased their target price on Amylyx Pharmaceuticals from $32.00 to $39.00 and gave the stock a "buy" rating in a report on Thursday, October 15th. Finally, Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Amylyx Pharmaceuticals in a research report on Tuesday. Two investment analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, Amylyx Pharmaceuticals has a consensus rating of "Buy" and an average price target of $44.14.

Amylyx Pharmaceuticals Price Performance

Shares of AMLX stock opened at $29.50 on Thursday. The firm has a 50 day moving average of $30.00 and a two-hundred day moving average of $20.41. Amylyx Pharmaceuticals has a 52 week low of $10.83 and a 52 week high of $41.14.

Amylyx Pharmaceuticals (NASDAQ:AMLX - Get Free Report) last issued its earnings results on Thursday, November 5th. The company reported ($0.38) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.38). As a group, analysts anticipate that Amylyx Pharmaceuticals will post -1.48 EPS for the current year.

Insider Activity

In related news, CFO James M. Frates sold 10,810 shares of Amylyx Pharmaceuticals stock in a transaction that occurred on Thursday, September 10th. The stock was sold at an average price of $32.36, for a total transaction of $349,811.60. Following the completion of the sale, the chief financial officer directly owned 233,625 shares of the company's stock, valued at approximately $7,560,105. This trade represents a 4.42% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director George M. Milne, Jr. sold 30,000 shares of the firm's stock in a transaction on Monday, October 5th. The stock was sold at an average price of $27.70, for a total value of $831,000.00. Following the completion of the sale, the director directly owned 782,881 shares of the company's stock, valued at $21,685,803.70. This represents a 3.69% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 60,374 shares of company stock worth $1,815,257 in the last three months. 10.90% of the stock is owned by insiders.

Institutional Trading of Amylyx Pharmaceuticals

Institutional investors and hedge funds have recently made changes to their positions in the company. BlackRock Inc. acquired a new stake in shares of Amylyx Pharmaceuticals during the 2nd quarter worth about $158,534,000. Jupiter Topco LLC purchased a new stake in Amylyx Pharmaceuticals in the second quarter valued at approximately $94,014,000. Janus Henderson Group PLC boosted its holdings in Amylyx Pharmaceuticals by 11.6% in the 1st quarter. Janus Henderson Group PLC now owns 4,986,073 shares of the company's stock worth $69,257,000 after acquiring an additional 520,201 shares during the period. Alyeska Investment Group L.P. bought a new position in Amylyx Pharmaceuticals during the second quarter worth $18,912,000. Finally, Almitas Capital LLC bought a new stake in shares of Amylyx Pharmaceuticals during the second quarter valued at approximately $17,509,000. 95.84% of the stock is currently owned by institutional investors.

Key Stories Impacting Amylyx Pharmaceuticals

Here are the key news stories impacting Amylyx Pharmaceuticals this week:

• Positive Sentiment: HC Wainwright reiterated its “Buy” rating and $55 price target, while forecasting quarterly losses to narrow from $0.38 per share in Q1 2027 to $0.32 in Q4 2027. The rating and target may support investor optimism. Analyst estimates and rating
• Neutral Sentiment: Amylyx reported a Q3 2026 loss of $0.38 per share, matching the consensus estimate. The in-line result was not a positive earnings surprise. Third-quarter financial results
• Neutral Sentiment: The company’s Q3 2026 earnings-call transcript was published, but the provided coverage does not detail additional announcements or outlook changes from the call. Q3 2026 earnings-call transcript

About Amylyx Pharmaceuticals

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.